NeuroBo Pharmaceuticals, Inc. Form 10-Q Summary
Filing identity: The supplied filing identifies the registrant as NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), not Metavia Inc. It covers the quarterly period ended September 30, 2023 and was filed November 13, 2023. The financial statements are unaudited.
Business Context and Reporting Period
NeuroBo is a clinical-stage biotechnology company developing cardiometabolic therapies. Its primary programs are DA-1241, a GPR119 agonist for NASH and type 2 diabetes, and DA-1726, a GLP1R/GCGR dual agonist for obesity and potentially NASH. The company initiated a Phase 2a DA-1241 study during the third quarter and planned to submit an IND for DA-1726 and initiate Phase 1 trials during the fourth quarter of 2023.
The company discontinued clinical development of ANA001 and COVID-19-related development of gemcabene in June 2023. Legacy programs remain potential out-licensing or acquisition opportunities.
Financial Metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $2.3 million, versus $0.6 million | $5.3 million, versus $2.5 million |
| General and administrative expense | $1.6 million, versus $2.5 million | $4.9 million, versus $6.7 million |
| Total operating expenses | $3.9 million, versus $3.1 million | $10.2 million, versus $9.2 million |
| Net loss | $3.8 million, versus $3.1 million | $7.2 million, versus $9.3 million |
| Net loss per share | $0.09, versus $3.50 | $0.18, versus $10.45 |
| Operating cash flow | Not separately presented | $(7.4) million, versus $(9.9) million |
There is no meaningful revenue or profit margin to analyze because the company has not generated product or collaboration revenue. The nine-month loss improved primarily because of a $2.9 million gain from the change in fair value of warrant liabilities and lower general and administrative costs, partly offset by higher development spending.
At September 30, 2023, cash was $25.8 million, compared with $33.4 million at December 31, 2022. Total assets were $26.4 million and total liabilities were $4.9 million. Liabilities included $1.1 million of warrant liabilities and $0.2 million of operating lease liabilities. No conventional debt balance was disclosed. Stockholders’ equity was $21.6 million, and accumulated deficit was $103.0 million.
Material Changes Versus the Prior Comparable Period
- Quarterly R&D expense increased $1.7 million, primarily from DA-1241 clinical trial costs and toxicology work.
- Nine-month R&D expense increased $2.8 million due to DA-1241 clinical, toxicology and manufacturing activities.
- Quarterly and nine-month G&A expense declined $0.9 million and $1.8 million, respectively, mainly because of lower professional fees, insurance costs and stock-based compensation.
- Cash used in operations improved by $2.5 million to $7.4 million for the nine months, although the company continued to consume cash.
- Common shares outstanding increased to 38.4 million at September 30, 2023 from 25.4 million at December 31, 2022. Warrants were exchanged for approximately 12.8 million shares during the nine months.
- A new Boston headquarters lease commenced September 1, 2023, with a three-year initial term and recognized lease liabilities of $0.2 million.
Guidance, Outlook, Risks and Unusual Items
- Management expects existing cash to fund operations into the fourth quarter of 2024, but states that substantial doubt exists regarding the company’s ability to continue as a going concern.
- Additional financing will be required. Potential sources include equity, debt, collaborations and licensing transactions. Equity financing could materially dilute existing holders, while debt financing could impose restrictive covenants.
- If additional capital is unavailable, the company may slow or halt ongoing and planned clinical trials.
- The DA-1241 Phase 2a study is a 16-week, placebo-controlled trial with planned enrollment of up to 55 subjects in Part 1 and up to 43 subjects in Part 2. Its primary endpoint is change in ALT at Week 16.
- The company had not regained compliance with Nasdaq’s $1.00 minimum bid-price requirement. Nasdaq granted an extension to February 5, 2024. The board may implement a previously approved one-for-five to one-for-eight reverse stock split.
- Internal control over financial reporting remained ineffective because of material weaknesses involving segregation of duties, system access and supervision and review of financial reporting. Remediation was in progress but not complete.
- The company has no material legal proceedings identified by management, and no milestone or royalty liabilities were accrued under its licensing and merger-related arrangements as of September 30, 2023.
- Subsequent to quarter-end, 383,333 Series B warrants were exchanged for common shares.
Most Important Facts for Investors to Verify
- Confirm the registrant identity: the supplied filing is for NeuroBo Pharmaceuticals, Inc., not Metavia Inc.
- Assess the going-concern disclosure, projected cash runway and the company’s ability to secure financing before the stated fourth-quarter 2024 cash horizon.
- Track enrollment, safety and efficacy results for the DA-1241 Phase 2a study and the timing and acceptance of the DA-1726 IND.
- Verify Nasdaq compliance status, any reverse stock split decision and potential effects on liquidity and dilution.
- Review the impact of warrant exercises, outstanding warrants, stock-based awards and any future equity financing on share dilution.
- Monitor remediation of the material weaknesses in internal control over financial reporting.